BMY vs BIIB — Key Metrics

Metric BMY (BRISTOL MYERS SQUIBB CO) BIIB (BIOGEN INC)
Price59.56251.41
Market Cap121.75 Billion37.16 Billion
P/E (TTM)13.15106.53
P/B (Quarterly)5.3621.907
P/S (TTM)2.433.61
Net Profit Margin (TTM)18.53.4
Gross Margin (TTM)69.274.0
ROE (TTM)43.91.9
Revenue Growth YoY (TTM)n/an/a

Upfront Investment - S&P 500 Stock Comparison & AI Analysis

AI-powered analysis and comparison tools for S&P 500 stocks, helping investors make data-driven decisions with delayed market data and portfolio modeling.

BRISTOL MYERS SQUIBB CO
vs
 
BIOGEN INC
 
BRISTOL MYERS SQUIBB CO
vs
 
BIOGEN INC
Performance Comparison
AI Model Recommendation
BMY · BRISTOL MYERS SQUIBB CO

Greatly Outperform

87
UnderperformOutperform
BIIB · BIOGEN INC

Greatly Outperform

76
UnderperformOutperform
Recommendation Summary

Both stocks are projected to significantly outperform the market over the next year. If you have to make a choice, Upfront Recommendation: BMY.

Financial Metrics
Prices delayed ~15 min
BMY Metrics BIIB
$59.56 Price $251.41
— Market Capitalization —
13.15 Price to Earnings Ratio 106.53
2.43 Price to Sales 3.61
13.11 Price to FCF Ratio 18.09
3.51 Price to Gross Profit 4.88
11.53 Price to R&D 17.27
4.09 Price to Current Assets 4.9

BMY vs BIIB at a glance

Bristol Myers Squibb CO (BMY) and Biogen INC (BIIB) are both Drug Manufacturers - General companies in the Healthcare sector. BMY is the larger, at $121.7 billion in market value against $37.2 billion for BIIB, about 3.3 times the size.

On trailing-twelve-month figures, BMY trades at 13.2 times trailing earnings and BIIB at 106.5; net profit margins are 18.5% and 3.4%.

The Upfront Investment model currently rates both Greatly Outperform as of November 18, 2026. The rating ranks the model's medium-term return forecast against the other stocks it scores; it is a statistical forecast, not investment advice.